Randomised controlled trial
Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification
- Randomised controlled trial
- placebo-controlled
- 2 centres
Authors' conclusion
The findings of this study suggest that supplementation with MK-7 for 2 years may slow calcification in noncalcified plaques of patients with symptomatic CAD.
Study context
- Population
- Symptomatic patients with coronary artery disease (CAD) and coronary artery calcification (CAC) score 50–400 Agatston units (AU), Netherlands90 per group randomised
- Participants
- 180 patients
- Comparison
- MK-7 vs placebo
- Active treatmentn = 85
- Placebon = 82reference
- Primary endpoint
- Evolution of CAC score and calcium mass on computed tomography (CT)
- Follow-up
- 1 and 2 years
Primary result
As reported in the abstract
CAC score (Agatston units) · baseline, 1 and 2 years
| Group | Baseline | Year 1 | Year 2 |
|---|---|---|---|
| Placebo | 145 (99-217) AU | 173 (119-297) AU | 214 (148-344) AU |
| Active treatment | 135 (89-226) AU | 150 (110-254) AU | 184 (122-298) AU |
- Active treatment vs Placebo: P = 0.02 — significant even after adjustment for covariates
Secondary outcomes
| Outcome | Values |
|---|---|
| Plasma MK-7 (MK-7 group) | MK-7 median 6.56 (IQR 2.04–10.35) µg/L · Baseline 0.50 [0.32-0.77] µg/L |
- Plasma MK-7 (MK-7 group): P < .001
CAC increase vs noncalcified plaques becoming partially calcified
- Correlation R2
- 0.17
- P = .04
Safety
Adverse effects
- No significant adverse effects observed
Original publication
Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification. JAMA Cardiol. Published 1 August 2026. doi:10.1001/jamacardio.2026.1279
Summarised from the published abstract; every number is checked against it